Tocris Cookson Limited

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Tocris Cookson Limited - overview

Established

1982

Location

Bristol, -, UK

Primary Industry

Chemicals

About

Tocris Cookson Limited specializes in the development and provision of high-performance life science reagents aimed at enhancing research in oncology, immunology, and neuroscience. Founded in 1982, Tocris Cookson Limited operates as a provider of life science reagents. The company has consistently focused on delivering innovative tools for research and has established its global headquarters in Bristol, UK. It has grown through strategic initiatives aimed at enhancing its product offerings.


Tocris Bioscience specializes in high-performance life science reagents, offering a diverse portfolio designed to support various research areas, including cancer, immunology, and neuroscience. Their core products encompass small molecules, peptides, and specific research tools such as ProtiFect STAR™ Protein Transfection Reagent, which has received recognition for its innovative contributions to protein delivery in cellular studies. Tocris’ reagents are available in ready-to-use formats, including 10 mM sterile-filtered solutions, addressing the needs of researchers in both academic and industrial laboratories. The company serves a global customer base, including research institutions and pharmaceutical companies across North America, Europe, and Asia, providing essential tools for experimental validation and therapeutic development.


Tocris Bioscience generates revenue through direct sales of its life science reagents and research tools, typically engaging in B2B transactions with academic and commercial laboratories. The company’s transactional structure involves customized orders based on the specific needs of its clients, with products sold individually or bundled in bulk quantities. The pricing strategy for Tocris’ flagship products, such as their Fluorescent Dyes and Probes as well as the lipid nanoparticle (LNP) formulations for mRNA delivery, is structured to accommodate various research budgets while ensuring accessibility to cutting-edge technology. Tocris also engages in promotional activities, offering discounts on selected reagents to incentivize purchases and foster long-term partnerships within the research community.


Primary Industry

Chemicals

Sub Industries

Chemicals

Website

www.tocris.com

Verticals

Manufacturing

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.